ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Reply to T. Kaneko et al.
Marie Flannery, Eva Culakova, Supriya Mohile
Abstract readLetterComment
In one paragraphArticle in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
3 authors.
Marie FlanneryMarie Flannery, RN, PhD, School of Nursing, University of Rochester Medical Center, Rochester, NY; Eva Culakova, MS, PhD, Department of Surgery, University of Rochester Medical Center, Rochester, NY; and Supriya Mohile, MD, MS, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0003-2957-8482 Eva CulakovaMarie Flannery, RN, PhD, School of Nursing, University of Rochester Medical Center, Rochester, NY; Eva Culakova, MS, PhD, Department of Surgery, University of Rochester Medical Center, Rochester, NY; and Supriya Mohile, MD, MS, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0002-9852-6515 Supriya MohileMarie Flannery, RN, PhD, School of Nursing, University of Rochester Medical Center, Rochester, NY; Eva Culakova, MS, PhD, Department of Surgery, University of Rochester Medical Center, Rochester, NY; and Supriya Mohile, MD, MS, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
Funding
URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7MUTMB OAIC Research Education Component (REC)P30AG024832 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI JAMES S. GOODWIN, MD, MELISSA M. MORROW · 2005 to 2026
$26.7MUnderstanding Treatment Tolerability in Older Patients with CancerU01CA233167 · NCI · UNIVERSITY OF ROCHESTER · PI MOHILE, SUPRIYA G. · 2018 to 2023
$3.5MReducing Chemotherapy Toxicity in Older AdultsR01CA177592 · NCI · UNIVERSITY OF ROCHESTER · PI MOHILE, SUPRIYA G. · 2013 to 2018
$3.0MA Patient-Oriented Research Program in Geriatric OncologyK24AG056589 · NIA · UNIVERSITY OF ROCHESTER · PI Supriya G. Mohile · 2018 to 2026
$1.5MNCI NIH HHS R01 CA177592NCI NIH HHS U01 CA233167NCI NIH HHS UG1 CA189961NIA NIH HHS K24 AG056589NIA NIH HHS P30 AG024832
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID36930847
PMCPMC10414705
What Socratic holds
Textmetadata
Read underepoch 390